APA (7th ed.) Citation

KA, M., S, D., J, Y., Y, M., P, F., E, L., . . . G, C. (2021). LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(7), 2061. https://doi.org/10.1158/1078-0432.CCR-20-2563

Chicago Style (17th ed.) Citation

KA, Monaco, et al. "LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 27, no. 7 (2021): 2061. https://doi.org/10.1158/1078-0432.CCR-20-2563.

MLA (9th ed.) Citation

KA, Monaco, et al. "LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 27, no. 7, 2021, p. 2061, https://doi.org/10.1158/1078-0432.CCR-20-2563.